Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1895 results about "Lymphocyte" patented technology

A lymphocyte is one of the subtypes of a white blood cell in a vertebrate's immune system. Lymphocytes include natural killer cells (which function in cell-mediated, cytotoxic innate immunity), T cells (for cell-mediated, cytotoxic adaptive immunity), and B cells (for humoral, antibody-driven adaptive immunity). They are the main type of cell found in lymph, which prompted the name "lymphocyte".

An improved process for purification of fusion protein

The present invention relates to purification process of pharmacologically active cytotoxic T lymphocyte-associated 4-immunoglobulin (CTLA4-lg) fusion protein by using three column chromatography steps that provides purified form of the fusion protein, substantially free of misfolded species, charge variants and aggregates. A method for purifying a fusion protein from a protein mixture comprising a fusion protein and high molecular weight (HMW) impurity.
Owner:ACQUIOM AGENCY SERVICES LLC AS COLLATERAL AGENT

Anti-LAG3 antibodies and uses thereof

To provide antibodies that bind to lymphocyte activation gene 3 (LAG3) protein, which is a T cell co-inhibitor, and methods of use.SOLUTION: In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing means of treating a disease or disorder such as cancer or viral infection. The antibodies of the present invention are useful, inter alia, for targeting immune cells expressing LAG3 and for modulating LAG3 activity.SELECTED DRAWING: None
Owner:REGENERON PHARMACEUTICALS INC

Immune microbubble complex and its uses

The present invention relates to an immunomicrobubble complex and its uses. The immunomicrobubble complex (IMC) according to the present invention comprises microbubbles conjugated with an antibody, wherein the microbubbles have excellent stability and excellent antibody binding strength, and it has been confirmed that when the immunomicrobubble complex is treated with high-intensity focused ultrasound (HIFU), the anti-tumor effect is significantly enhanced and an immune-enhancing effect is exhibited. Therefore, the immunomicrobubble complex according to the present invention is expected to improve the delivery efficiency of the conjugated antibody and can be used for the diagnosis and treatment of cancer, and exhibits various functions in the field of immunotherapy, including a contrast effect, improvement of half-life, improvement of drug delivery, lymphocyte concentrating effect, cancer immunotherapy, and ultrasound-induced immunotherapy.
Owner:IMGT

Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody

This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.
Owner:BRISTOL MYERS SQUIBB CO

SIRP α, SIRP β 1, and SIRP γ antibodies and uses thereof

Provided herein are antibodies that bind signal regulatory protein gamma (SIRPγ), as well as SIRPα and / or SIRPβ1, and methods of using such antibodies (referred to as SIRP antibodies). In some embodiments, the SIRP antibodies are human monoclonal antibodies that bind human SIRPγ as well as SIRPα and / or SIRPβ1. In some embodiments, the SIRP antibodies provided herein are useful for treating a disease or condition associated with overactivation and / or hyperproliferation of lymphocytes, myeloid cells, or a combination thereof, or a disease or condition associated with SIRPα, SIRPβ1 and / or SIRPγ activity.
Owner:ELECTRA THERAPEUTICS INC

Difunctional cavings oligopeptide GK-8 for preventing and treating metabolic syndrome and improving immunity

The invention discloses a bifunctional cavings oligopeptide GK-8 for preventing and treating metabolic syndrome and improving immunity and application of the bifunctional cavings oligopeptide GK-8. The amino acid sequence of the cavings oligopeptide is Gly-Leu-Ser-Phe-Asp-Phe-Tyr-Lys (GLSFDFYK, called GK-8 for short). Experiments find that the GK-8 has the effects of preventing and treating the metabolic syndrome of the mice, specifically, the GK-8 can obviously reduce the body weight of the mice, improve fatty degeneration and obviously reduce insulin resistance of the mice; the levels of triglyceride TG, total cholesterol TC and low-density lipoprotein LDL-C in mouse serum are obviously reduced, and the level of high-density lipoprotein HDL-C is increased; meanwhile, it is found that the GK-8 significantly activates the immunoregulation ability of an immunosuppressive mouse induced by cyclophosphamide, for example, the weight, thymus index and spleen index of the immunosuppressive mouse are recovered; the multiplication capacity of T lymphocytes and B lymphocytes of the spleen of the mouse, the killing activity of NK cells and the like are enhanced. The bran oligopeptide GK-8 is expected to be further researched and developed into related medicine products for preventing and treating the metabolic syndrome and improving the immunity, and the bran oligopeptide GK-8 has a wide application prospect.
Owner:SHANXI UNIV

Lymphocyte targeted lentiviral vectors

Provided herein are lentiviral vectors comprising a mutated, heterologous envelope protein, a targeting protein, and at least one transgene for delivery to and expression by a cell characterized by the targeting protein. Also provided are methods and materials for producing the lentiviral vectors described herein, methods for transducing target cells, and cells transduced by lentiviral vectors according to the present disclosure.
Owner:KELONIA THERAPEUTICS INC

Combination therapy for lung cancer

The disclosure provides a method of treating a human subject afflicted with lung cancer (e.g., non-small cell lung cancer (NSCLC)) with a programmed death-1 (PD-1) pathway inhibitor (e.g., an anti-PD-1 antibody) and a concurrent chemoradiotherapy (CCRT, e.g., a platinum doublet chemotherapy (PDCT) and a radiation therapy) followed by a combination of a PD-1 pathway inhibitor (e.g., an anti-PD-1 antibody) and a lymphocyte activation gene-3 (LAG-3) antagonist (e.g., an anti-LAG-3 antibody). In some aspects, the method comprises a recovery period that begins upon completion of the treatment with the PD-1 pathway inhibitor and the CCRT and ends at the start of the treatment with the combination of the PD-1 pathway inhibitor and the LAG-3 antagonist.
Owner:BRISTOL MYERS SQUIBB CO

T lymphocytes targeting CLD18A2 and preparation method and application thereof

The present invention relates to T lymphocytes targeting CLD18A2 and a preparation method and application thereof. The inventors have successfully found a target gene CLD18A2 suitable for developing CAR T cells from a number of tumor-related genes for the first time, and successfully prepared CAR T cells targeting CLD18A2, thereby providing a new treatment method for pancreatic cancer, gastric cancer and other tumors.
Owner:CARSGEN LIFE SCI CO LTD

Automatic suction device for T lymphocytes

The invention belongs to the technical field of inspection and extraction, and particularly relates to an automatic T lymphocyte suction device which comprises an automatic suction device body, the automatic suction device body comprises a bearing table, a rotating disc with a circumferential rotating function is arranged on the bearing table, and a plurality of centrifugal assemblies are evenly distributed on the rotating disc. A centrifugal tube feeding assembly facilitating feeding of centrifugal tubes is arranged in front of one side of the bearing table, a tube carrying and conveying assembly is arranged on the portion, located on one side of the centrifugal tube feeding assembly, of the bearing table, a tube feeding mechanism is arranged at the end of the conveying belt mechanism, and a reaction reagent adding assembly is arranged on one side of the tube carrying and conveying assembly. A sample feeding assembly is arranged on one side of the upper portion of the workbench, and a first suction assembly is arranged above the multi-direction adjusting assembly. According to the invention, multiple samples can be processed in batches, the working efficiency and the cell extraction purity are improved, the influence of manual operation on the result is reduced, the accuracy of the detection effect is ensured, and the use requirements are met.
Owner:JINAN D A MEDICAL TESTING CENT CO LTD

Antibodies that bind TSLP and methods of use

Described herein are novel and improved antibodies that bind to thymic stromal lymphopoietin (TSLP) and methods of use thereof. In certain aspects, described herein are methods of inhibiting TSLP biological activity. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of TSLP. In certain aspects, described herein are methods of treating asthma by administering anti-TSLP antibodies.
Owner:PARAGON THERAPEUTICS INC

Methods for the treatment of b cell malignancies using adoptive cell therapy

Provided are adoptive cell therapy methods involving the administration of doses of cells for treating B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with chronic lymphocytic leukemia (CLL). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods involve prior administration of a lymphodepleting therapy, such as prior administration of fludaribine and / or another lymphodepleting chemotherapeutic agent, for example cyclophosphamide. In some embodiments, features of the methods include an increase in complete remission, overall survival and / or progression free survival of subjects treated in accord with the provided methods.
Owner:JUNO THERAPEUTICS INC +1

Anti-PD1 monoclonal antibody, pharmaceutical composition thereof and use thereof

An anti-PD1 (programmed cell death 1) monoclonal antibody or an antigen-binding fragment thereof, a pharmaceutical composition thereof and use thereof. The heavy chain variable region of the monoclonal antibody comprises CDRs (complementary determining region) of amino acid sequences as shown in SEQ ID NO:9-11; and / or the light chain variable region of the monoclonal antibody comprises CDRs of amino acid sequences as shown in SEQ ID NO: 12-14. The monoclonal antibody can bind to PD1 specifically, relieve immunosuppression of PD1 on an organism specifically and activate T lymphocytes.
Owner:CTTQ AKESO (SHANGHAI) BIOMED TECH CO LTD

Antigen binding protein targeting PD-L1 and CD40 as well as preparation and application thereof

The invention discloses an antigen binding protein targeting PD-L1 and CD40 as well as preparation and application of the antigen binding protein. According to the antigen binding protein targeting PD-L1 and CD40, a PD-1 / PD-L1 inhibitory signal channel is blocked, the antigen binding protein acts on an activated CD40 receptor, and antigen presenting cells and lymphocytes are activated at the same time, so that a remarkable synergistic anti-tumor effect is achieved; meanwhile, the activation of the antigen binding protein targeting PD-L1 and CD40 on immune cells only occurs at a tumor microenvironment part, so that the problems of systematic drug toxicity and side effects are remarkably solved; therefore, the antigen binding protein targeting PD-L1 and CD40 can play an excellent anti-tumor drug effect under the precondition that the antigen binding protein targeting PD-L1 and CD40 is very safe.
Owner:HARBOUR BIOMED (SHANGHAI) CO LTD

Antagonistic anti-tumor necrosis factor receptor superfamily antibodies

Antagonistic TNFR superfamily polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs). For example, antibodies of the invention include antagonistic TNFR2 antibodies and antigen-binding fragments thereof, and can be used to suppress the T-reg-mediated deactivation of tumor reactive T-lymphocytes, as well as to treat a wide variety of cancers and infectious diseases.
Owner:THE GENERAL HOSPITAL CORP

Anti-pancreatic cancer dendritic cell vaccine as well as preparation method and application thereof

The invention provides an anti-pancreatic cancer dendritic cell vaccine as well as a preparation method and application thereof, and belongs to the technical field of tumor vaccines. The anti-pancreatic cancer dendritic cell vaccine comprises dendritic cells loaded with at least one of the following antigens: induced pluripotent stem cell lysate and induced pluripotent stem cell exosome. The vaccine can obviously stimulate proliferation of T cells and can specifically induce proliferation of CD8 + T lymphocytes, so that the vaccine has obvious killing activity on three pancreatic cancer tumor cell lines. Meanwhile, the vaccine shows a good anti-pancreatic cancer effect in preventive inoculation in a human immune reconstruction mouse pancreatic cancer tumor model.
Owner:SHANDONG GOLDEN BRICK BIOTECHNOLOGY CO LTD

Pharmaceutical composition for promoting aTreg cell differentiation and application thereof

The invention discloses a pharmaceutical composition for promoting aTreg cell differentiation and application thereof, and relates to the field of biological medicine, and the pharmaceutical composition comprises zinc salt, a basic cell culture medium, fetal calf serum, antibiotic, L-glutamine and a pH buffer agent. According to the application, the basic cell culture medium is used for providing basic nutrition required by cell growth for lymphocytes, the fetal calf serum is used for providing growth factors, hormones, adhesion proteins and nutrient substances required by cell growth for the lymphocytes, and the antibiotics are used for preventing bacterial infection; l-glutamine provides key amino acid for cell energy metabolism and participates in synthesis of protein and nucleic acid, zinc salt provides zinc ions, and under the comprehensive action, the proportion of Treg cells and aTreg cells differentiated from lymphocytes in peripheral blood mononuclear cells is increased.
Owner:RENMIN HOSPITAL OF WUHAN UNIVERSITY (HUBEI GENERAL HOSPITAL)

Reagent for rapidly distinguishing bacterial virus infection and application

The invention discloses a reagent for rapidly distinguishing bacterial and virus infection and application, belongs to the field of molecular biology, relates to medical and biotechnology, and aims to solve the problem that a traditional method cannot clearly distinguish bacterial infection from virus infection. The reagent comprises five antibodies marked with different fluorescence. The five antibodies are all mouse anti-human or rabbit anti-human antibodies, and targets corresponding to the five antibodies are respectively CD45, CD14, CD64, CD169 and HLA-DR (human leukocyte antigen-DR). The tail end of the antibody is connected with different fluorescein through chemical reaction; fluorescence labeling is performed on neutrophils, mononuclear cells and lymphocytes in peripheral blood through an antibody combination of CD molecules, and corresponding infection indexes are calculated through a flow cytometry method, so that the infection type (bacterial / virus infection) of a patient is quickly distinguished and judged.
Owner:SUZHOU ZHIYAN MEDICAL TECHNOLOGY CO LTD

Application of T lymphocyte embedded with B7-H3 receptor in treatment of head and neck tumors

The invention relates to the field of tumor cell therapy, in particular to application of T lymphocyte chimeric with a B7-H3 receptor to treatment of head and neck tumors, and provides an anti-B7-H3 scFv, the scFv comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises an HCDR region and an HFR region, and the light chain variable region comprises an LCDR region and an LFR region; compared with a wild type scFv sequence, the scFv sequence has the advantage that a plurality of amino acids with positive charges in the HFR region and / or the LFR region are mutated into amino acids without charges. According to the invention, positive charge plaques on the CAR surface of an scFv sequence of a B7-H3 human-derived monoclonal antibody MGA271 are changed in a charged amino acid mutation manner, so that a B7-H3. CAR-T cell is optimized, and it is proved that the B7-H3. CAR-T cell optimized by PCP can effectively kill B7-H3 positive tumor cells in vivo and in vitro; and a new method and thought are provided for clinical targeted treatment of B7-H3 positive solid tumors.
Owner:EYE & ENT HOSPITAL SHANGHAI MEDICAL SCHOOL FUDAN UNIV

Methods, kits, agents and apparatuses for transduction

Provided herein are methods for transducing a plurality of cells in a composition of cells, such as a population of lymphocytes, containing viral particles. In some aspects, provided methods and reagents for the transduction of cell populations involve binding of agents to a molecule on the surface of the cells. In some cases, the reagents are multimerization reagents and the one or more agents are multimerized by reversibly binding to the reagent. In some aspects, the multimerized agent can provide for transduction and / or expansion or proliferation or other stimulation of a population of cells, and then such agents can be removed by disruption of the reversible bond. Also provided are compositions, apparatus and methods of use thereof.
Owner:JUNO THERAPEUTICS INC

Method for detecting high-sensitivity tumor residues in TIL product and application of method

The invention discloses a method for detecting high-sensitivity tumor cell residues in a TIL product and application of the method, the detection method is used for detecting the tumor cell residues in tumor infiltration lymphocytes, specific primers are adopted in the detection process, and the sequences of the specific primers are shown as follows: a forward primer is 5 '-TCCGCGAGGTCACCATAAC-3', and a reverse primer is 5 '-GCTCTGTCAACTCGTCTCAT-3'; according to the method, the detection sensitivity of the tumor cell residues can be improved, and the lower detection limit of the detection method reaches five hundred thousand.
Owner:NINGBO XINUOSAI BIOTECHNOLOGY CO LTD

Traditional Chinese medicine composition for treating triple negative breast cancer and application thereof

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating triple negative breast cancer and application thereof. The traditional Chinese medicine composition is prepared from the following main active ingredients in parts by mass: 20 to 40 parts of radix astragali seu hedysari, 10 to 20 parts of rhizoma curcumae, 10 to 20 parts of herba hedyotidis diffusae, 5 to 15 parts of fructus aurantii immaturus, 5 to 15 parts of radix bupleuri, 5 to 15 parts of radix paeoniae alba and 5 to 15 parts of liquorice root. Animal experiments show that the traditional Chinese medicine composition can significantly inhibit tumor growth and pulmonary metastasis of triple-negative breast cancer tumor-bearing mice, increase the proportion of CD8 + T lymphocytes in blood, reduce the proportion of MDSCs, significantly down-regulate the expression of pro-inflammatory cytokines such as IL-6, IL-1alpha, CXCL1 and GM-CSF in serum, and cooperate with PD-L1 immunotherapy to achieve a synergistic effect. And the whole blood and liver and kidney function indexes are in a normal range. Therefore, the traditional Chinese medicine composition disclosed by the invention can be used for effectively inhibiting the tumor growth and pulmonary metastasis of the triple negative breast cancer, remodeling the immune state of an organism and reducing the release of proinflammatory factors, and is safe, reliable, free of obvious liver and kidney toxicity and blood toxicity and small in side effect.
Owner:GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE

Antibody capable of binding to thymic stromal lymphopoietin and use thereof

Disclosed are an antibody capable of binding to thymic stromal lymphopoietin and the use thereof. Disclosed are an anti-TSLP antibody, comprising a murine antibody, chimeric antibody and humanized antibody of the light chain and heavy chain variable regions of the anti-TSLP antibody and antigen-binding fragments thereof, or a pharmaceutically acceptable salt or solvent compound thereof, and the use thereof as a medicament for treating asthma, especially the use thereof in the preparation of a drug for treating TSLP-positive diseases or conditions.
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1

Method for predicting child non-reactive Kawasaki disease based on T lymphocyte activation related cytokines

The invention provides an application of a T lymphatic activation related cytokine as a biomarker in prediction of children immune globulin non-reactive Kawasaki disease. The team finds that in patients of an IVIG sensitive group and an IVIG non-response group, differences of expression levels of IL-6 and IL-17 before and after treatment have statistical significance; meanwhile, ROC curve analysis shows that IL-6 and IL-17 serve as early warning signals, and the prediction efficiency of the IVIG-unreacted Kawasaki disease is remarkably superior to that of existing prediction factors. Particularly, the levels of IL-6 and IL-17 are re-evaluated after initial treatment, so that the early prediction accuracy of the IVIG unresponsive Kawasaki disease can be further improved. By introducing IL-6 and IL-17 as novel biomarkers, early accurate prediction of the IVIG unresponsive Kawasaki disease is realized. Compared with the prior art, the method can provide a quicker and more accurate risk assessment basis for clinicians, so that early recognition of high-risk patients, optimization of subsequent treatment schemes and reduction of serious complications are facilitated, and a new thought and direction are provided for clinical diagnosis and treatment.
Owner:HANGZHOU CHILDRENS HOSPITAL

Treatment of NSCLC patients with tumor infiltrating lymphocyte therapies

ActiveUS12553029B2Organic active ingredientsPeptide/protein ingredientsAntiendomysial antibodiesTumor infiltrating lymphocyte therapy
The present invention provides improved and / or shortened processes and methods for preparing TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy for the treatment of non-small cell lung carcinoma (NSCLC), wherein the NSCLC is refractory to treatment with an anti-PD-1 antibody and / or anti-PD-L1 antibody and / or VEGF inhibitor, or wherein the NSCLC has a predetermined tumor proportion score (TPS).
Owner:IOVANCE BIOTHERAPEUTICS INC

Method for culturing CIK (cytokine-induced killer) cells and application thereof

The invention discloses a method for culturing CIK (Cytokine-Induced Killer) cells and application thereof. The method comprises the following steps: recovering cord blood, mixing and centrifuging the recovered cord blood and a buffer solution, re-suspending and precipitating, centrifuging again to obtain cord blood mononuclear cells, inoculating the cord blood mononuclear cells into an activation culture medium, and culturing to obtain the CIK cells, the buffer solution contains L-proline, human recombinant DNA enzyme and angelica polysaccharide. According to the method, the mononuclear cells can be separated from the umbilical cord blood preserved by liquid nitrogen, the utilization rate of the umbilical cord blood which can only be discarded due to insufficient cells is increased, the traditional lymphocyte separation process is optimized, the recovery rate of the mononuclear cells is increased, and the cost is reduced. The method provided by the invention can be used for culturing dozens to ten billions of CIK cells from a small amount of cryopreserved cord blood, and has huge advantages in the field of CIK cell culture and application.
Owner:ZHEJIANG LVKOU BIOTECHNOLOGY CO LTD

A method for preparing a universal all-pig monoclonal antibody

The present invention belongs to the technical field of monoclonal antibody preparation, and specifically relates to a method for preparing a universal whole-pig monoclonal antibody. The present invention is based on single B cell antibody preparation technology, and antigen-specific single B lymphocytes are separated from the peripheral blood of immune pigs or clinically recovered pigs by flow cytometry sorting technology; according to the pig immunoglobulin IgG antibody gene sequence in the database, primers are designed to specifically amplify the complete coding genes of antibody heavy and light chains in pig single B cells and add His tags, and pCDNA3.1-Leader is used as a eukaryotic expression vector to construct a recombinant vector of complete coding genes for antibody light and heavy chains, and natural whole-pig monoclonal antibodies are expressed by mammalian cells. The present invention establishes a universal whole-pig monoclonal antibody preparation method for the first time, which can be used for the preparation and screening of pig monoclonal antibody libraries of different pathogens. Compared with other antibody preparation methods, it has the advantages of high throughput, whole pig source, good diversity, complete antibodies and natural pairing, etc., which provides technical support for the rapid preparation and screening of pig monoclonal antibodies and has broad application prospects.
Owner:CHINA INST OF VETERINARY DRUG CONTROL